Drug Repurposing to Identify Therapeutics Against COVID 19 with SARS-Cov-2 Spike Glycoprotein and Main Protease as Targets: An in Silico Study

Kumar, Arun; Sharanya, C. S.; Abhithaj, J; Sadasivan, C

doi:10.26434/chemrxiv.12090408

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A hypergeometric test returned a p-value of 3.59e-03, demonstrating the reliability and validity of our computational approaches. 30 further drugs that we identified have also been reported as being potential candidates against COVID-19 (Courtney J. Mycroft-West, Dunhao Su , Yong Li , Scott E. Guimond, Timothy R. Rudd and Elli, Gavin Miller, Quentin M. Nunes, Patricia Procter, Antonella Bisio, Nicholas R. Forsyth, Jeremy E. Turnbull, Marco Guerrini, David G. Fernig, Edwin A. Yates, 2020;Criado et al, 2020;Kuleshov et al, 2020;kumar, arun;C.S, Sharanya;J, Abhithaj;MirIbrahim Sajid, Javeria Tariq, SheharBano Awais, ZehraNaseem, SamiraShabbir Balouch, 2020;Shin et al, 2020). Thus, drug efficacy simulation has revealed 70 drugs in total that are either in COVID-19 clinical trials or being considered as potential drug candidates in pre-clinical studies, supporting the strength of our approach.…”

Section: An In Silico Drug Simulation On the Key Pathway Of Sip Netwomentioning

confidence: 93%

Identification of SARS-CoV-2 induced pathways reveal drug repurposing strategies

Han

Hwang

Tzelepis

et al. 2020

Preprint

View full text Add to dashboard Cite

The global outbreak of SARS-CoV-2 necessitates the rapid development of new therapies against COVID-19 infection. Here, we present the identification of 200 approved drugs, appropriate for repurposing against COVID-19. We constructed a SARS-CoV-2-induced protein (SIP) network, based on disease signatures defined by COVID-19 multi-omic datasets(Bojkova et al., 2020; Gordon et al., 2020), and cross-examined these pathways against approved drugs. This analysis identified 200 drugs predicted to target SARS-CoV-2-induced pathways, 40 of which are already in COVID-19 clinical trials(Clinicaltrials.gov, 2020) testifying to the validity of the approach. Using artificial neural network analysis we classified these 200 drugs into 9 distinct pathways, within two overarching mechanisms of action (MoAs): viral replication (130) and immune response (70). A subset of drugs implicated in viral replication were tested in cellular assays and two (proguanil and sulfasalazine) were shown to inhibit replication. This unbiased and validated analysis opens new avenues for the rapid repurposing of approved drugs into clinical trials.

show abstract

Section: An In Silico Drug Simulation On the Key Pathway Of Sip Netwomentioning

confidence: 93%

Identification of SARS-CoV-2 induced pathways reveal drug repurposing strategies

Han

Hwang

Tzelepis

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies

et al. 2021

View full text Add to dashboard Cite

The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates the rapid development of new therapies against coronavirus disease 2019 (COVID-19) infection. Here, we present the identification of 200 approved drugs, appropriate for repurposing against COVID-19. We constructed a SARS-CoV-2–induced protein network, based on disease signatures defined by COVID-19 multiomics datasets, and cross-examined these pathways against approved drugs. This analysis identified 200 drugs predicted to target SARS-CoV-2–induced pathways, 40 of which are already in COVID-19 clinical trials, testifying to the validity of the approach. Using artificial neural network analysis, we classified these 200 drugs into nine distinct pathways, within two overarching mechanisms of action (MoAs): viral replication (126) and immune response (74). Two drugs (proguanil and sulfasalazine) implicated in viral replication were shown to inhibit replication in cell assays. This unbiased and validated analysis opens new avenues for the rapid repurposing of approved drugs into clinical trials.

show abstract

An Update of Carbazole Treatment Strategies for COVID-19 Infection

et al. 2023

View full text Add to dashboard Cite

The Coronavirus disease 2019 (COVID-19) outbreak was declared by the World Health Organization (WHO) in March 2020 to be a pandemic and many drugs used at the beginning proved useless in fighting the infection. Lately, there has been approval of some new generation drugs for the clinical treatment of severe or critical COVID-19 infections. Nevertheless, more drugs are required to reduce the pandemic’s impact. Several treatment approaches for COVID-19 were employed since the beginning of the pandemic, such as immunomodulatory, antiviral, anti-inflammatory, antimicrobial agents, and again corticosteroids, angiotensin II receptor blockers, and bradykinin B2 receptor antagonists, but many of them were proven ineffective in targeting the virus. So, the identification of drugs to be used effectively for treatment of COVID-19 is strongly needed. It is aimed in this review to collect the information so far known about the COVID-19 studies and treatments. Moreover, the observations reported in this review about carbazoles as a treatment can signify a potentially useful clinical application; various drugs that can be introduced into the therapeutic equipment to fight COVID-19 or their molecules can be used as the basis for designing new antivirals.

show abstract

Drug Repurposing to Identify Therapeutics Against COVID 19 with SARS-Cov-2 Spike Glycoprotein and Main Protease as Targets: An in Silico Study

Cited by 3 publications

References 0 publications

Identification of SARS-CoV-2 induced pathways reveal drug repurposing strategies

Identification of SARS-CoV-2 induced pathways reveal drug repurposing strategies

Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies

An Update of Carbazole Treatment Strategies for COVID-19 Infection

Contact Info

Product

Resources

About